Cabozantinib in chemotherapy-pretreated metastatic castration-resistant prostate cancer: Results of a phase II nonrandomized expansion study Academic Article uri icon

Overview

MeSH Major

  • Anilides
  • Prostatic Neoplasms, Castration-Resistant
  • Protein Kinase Inhibitors
  • Pyridines
  • Receptor Protein-Tyrosine Kinases

abstract

  • The evidence suggests that cabozantinib has clinically meaningful activity in CRPC. Cabozantinib resulted in improvements in bone scans, pain, analgesic use, measurable soft tissue disease, circulating tumor cells, and bone biomarkers. Taken together, these phase II observations warrant further development of cabozantinib in prostate cancer.

publication date

  • October 20, 2014

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4383838

Digital Object Identifier (DOI)

  • 10.1200/JCO.2013.54.5954

PubMed ID

  • 25225437

Additional Document Info

start page

  • 3391

end page

  • 9

volume

  • 32

number

  • 30